HIND · XBRL financial data
Vyome Holdings financial statements, every fiscal year
The same tables from 8 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (HIND's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | †Dec 31, 2021 | Dec 31, 2022 | †Dec 31, 2023 | †Dec 31, 2024 | †Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | 257 | 320 |
| Revenue from contracts with customers | 1,588 | 13,600 | 11,240 | 8,678 | 8,006 | — |
| Cost of goods and services sold | 1,004 | 5,252 | 4,438 | 3,130 | 2,949 | 101 |
| Gross profit | 584 | 8,348 | 6,802 | 5,548 | 5,057 | 219 |
| Research and development | 2,450 | 2,522 | 2,537 | 2,315 | 1,803 | 588 |
| Selling, general and administrative | 8,776 | 9,165 | 14,093 | 7,548 | 899 | 2,366 |
| General and administrative | 10,527 | 24,410 | 17,250 | 10,324 | 6,931 | — |
| Total operating expenses | 12,536 | 64,849 | 53,153 | 20,931 | 12,785 | 10,671 |
| Operating income (loss) | (11,952) | (56,501) | (46,351) | (15,383) | (7,728) | (10,453) |
| Interest expense | — | — | — | — | 206 | 147 |
| Other income (expense) | (411) | — | 11 | 122 | 193 | 91 |
| Income tax expense (benefit) | 0 | (106) | (380) | 52 | 39 | — |
| Net income (loss) | (12,334) | (61,933) | (46,214) | (11,387) | (7,130) | (10,262) |
| Earnings per share, basic‡ USD per share | (23,726,060.19) | (21,374,829.00) | (9,310,875.51) | (163,303.69) | (345.75) | (4.86) |
| Earnings per share, diluted‡ USD per share | (23,726,060.19) | (21,374,829.00) | (9,310,875.51) | (163,303.69) | (345.75) | (4.86) |
| Weighted average shares, basic‡ thousands of shares | 0 | 0 | 0 | 0 | 21 | 2,161 |
| Weighted average shares, diluted‡ thousands of shares | 0 | 0 | 0 | 0 | 21 | 2,161 |
- ‡ Per-share figures and share counts are adjusted for the 1-for-50 stock split (December 2022); filings made before it reported them unadjusted.
- ‡ Per-share figures and share counts are adjusted for the 1-for-58.8235294117647 stock split (September 2024); filings made before it reported them unadjusted.
- ‡ Per-share figures and share counts are adjusted for the 1-for-58.13953488372093 stock split (September 2024); filings made before it reported them unadjusted.
- ‡ Per-share figures and share counts are adjusted for the 1-for-25 stock split (May 2025); filings made before it reported them unadjusted.
- † Share count changed about 2x in the period ending 2021-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 9x in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 1646x in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 16x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal years (HIND's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | †Dec 31, 2021 | Dec 31, 2022 | †Dec 31, 2023 | †Dec 31, 2024 | †Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 3,905 | 22,765 | 3,855 | 4,459 | 693 | 4,982 |
| Accounts receivable | — | — | — | 1,700 | 1,000 | 0 |
| Inventory | 2,244 | 3,003 | 3,611 | 3,741 | 2,460 | — |
| Prepaid and other current assets | 1,073 | 1,622 | 165 | 337 | 348 | 456 |
| Total current assets | 7,835 | 30,255 | 9,911 | 10,296 | 4,588 | 5,438 |
| Property and equipment, net | 957 | 1,454 | 698 | 60 | 38 | 46 |
| Right-of-use asset | 521 | 266 | 171 | 250 | 116 | 29 |
| Total assets | 10,617 | 54,258 | 11,142 | 10,663 | 4,793 | 6,497 |
| Accounts payable | 615 | 3,468 | 1,926 | 1,689 | 2,208 | 648 |
| Accrued liabilities | 3,630 | 3,169 | 5,040 | 1,814 | 1,688 | 639 |
| Current portion of long-term debt | 3,609 | — | — | — | — | — |
| Total current liabilities | 5,046 | 7,331 | 7,481 | 3,777 | 4,985 | 2,735 |
| Long-term debt | 430 | — | — | — | — | — |
| Lease liability, non-current | 438 | — | — | 151 | 41 | — |
| Total liabilities | 5,952 | 8,186 | 7,481 | 4,000 | 5,046 | 2,735 |
| Accumulated deficit | (184,764) | (576,760) | (624,187) | (635,574) | (642,704) | (87,564) |
| Total stockholders' equity | 4,665 | 46,072 | 3,661 | 6,663 | (253) | — |
| Total liabilities and equity | 10,617 | 54,258 | 11,142 | 10,663 | 4,793 | 6,497 |
| Common shares outstanding (cover page)‡ thousands of shares | 0 | 0 | 0 | 0 | 451 | 7,019 |
- ‡ Per-share figures and share counts are adjusted for the 1-for-50 stock split (December 2022); filings made before it reported them unadjusted.
- ‡ Per-share figures and share counts are adjusted for the 1-for-58.8235294117647 stock split (September 2024); filings made before it reported them unadjusted.
- ‡ Per-share figures and share counts are adjusted for the 1-for-58.13953488372093 stock split (September 2024); filings made before it reported them unadjusted.
- ‡ Per-share figures and share counts are adjusted for the 1-for-25 stock split (May 2025); filings made before it reported them unadjusted.
- † Share count changed about 2x in the period ending 2021-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 9x in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 1646x in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 16x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal years (HIND's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | †Dec 31, 2021 | Dec 31, 2022 | †Dec 31, 2023 | †Dec 31, 2024 | †Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Net income (loss) | (12,334) | (61,933) | (46,214) | (11,387) | (7,130) | (10,262) |
| Stock-based compensation | 1,089 | 12,752 | 2,087 | 766 | 184 | 577 |
| Net cash from operating activities | (10,409) | (15,375) | (21,902) | (16,960) | (4,427) | (3,749) |
| Purchases of property and equipment | 171 | — | — | — | — | — |
| Net cash from investing activities | (171) | 1,855 | (92) | (10) | 0 | — |
| Proceeds from issuing common stock | 0 | — | 639 | 13,438 | — | 1,283 |
| Proceeds from long-term debt | 430 | — | — | — | — | — |
| Repayments of long-term debt | 0 | 10,500 | — | — | — | — |
| Net cash from financing activities | 430 | 33,299 | 3,130 | 17,574 | 677 | 8,655 |
| Net change in cash | (10,150) | 19,808 | (18,860) | 604 | (3,766) | 4,880 |
- † Share count changed about 2x in the period ending 2021-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 9x in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 1646x in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 16x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Vyome Holdings | 7,888 | 27 | (904)* | 7.0M | 8.7 quarters | 10-QJun 30, 2026 |
| AIM ImmunoTech | 9,900 | 26 | (4,590)* | 30.4M | 2.2 quarters | 10-QJun 30, 2026 |
| Adial Pharmaceuticals | 28,712 | not reported | (6,363)* | 2.6M | 4.5 quarters | 10-Q/AJun 30, 2026 |
| PharmaCyte Biotech | 17,739 | 0 | (781) | 10.7M | 22.8 quarters | 10-QJul 31, 2026 |
| Natural Alternatives International | 7,388 | not reported | (1,066)* | 22.1M | 6.9 quarters | 10-KJun 30, 2026 |
| LFTD Partners | 1,504 | 8,705 | (555)* | 14.8M | 2.7 quarters | 10-QJun 30, 2026 |
| Biomerica | 2,733 | 1,265 | (802) | 4.6M | 3.4 quarters | 10-QAug 31, 2026 |
| America Great Health | 29 | 26 | 1.7* | 21.2B | — | 10-QMar 31, 2026 |
| Protagenic Therapeutics, Inc.\new | 566 | not reported | (944) | 1.8M | 0.6 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.